| Literature DB >> 26927810 |
Susan Byrne1, Carlo Dionisi-Vici2, Luke Smith3, Mathias Gautel3, Heinz Jungbluth4,5,6.
Abstract
Vici syndrome [OMIM242840] is a severe, recessively inherited congenital disorder characterized by the principal features of callosal agenesis, cataracts, oculocutaneous hypopigmentation, cardiomyopathy, and a combined immunodeficiency. Profound developmental delay, progressive failure to thrive and acquired microcephaly are almost universal, suggesting an evolving (neuro) degenerative component. In most patients there is additional variable multisystem involvement that may affect virtually any organ system, including lungs, thyroid, liver and kidneys. A skeletal myopathy is consistently associated, and characterized by marked fibre type disproportion, increase in internal nuclei, numerous vacuoles, abnormal mitochondria and glycogen storage. Life expectancy is markedly reduced.Vici syndrome is due to recessive mutations in EPG5 on chromosome 18q12.3, encoding ectopic P granules protein 5 (EPG5), a key autophagy regulator in higher organisms. Autophagy is a fundamental cellular degradative pathway conserved throughout evolution with important roles in the removal of defective proteins and organelles, defence against infections and adaptation to changing metabolic demands. Almost 40 EPG mutations have been identified to date, most of them truncating and private to individual families.The differential diagnosis of Vici syndrome includes a number of syndromes with overlapping clinical features, neurological and metabolic disorders with shared CNS abnormalities (in particular callosal agenesis), and primary neuromuscular disorders with a similar muscle biopsy appearance. Vici syndrome is also the most typical example of a novel group of inherited neurometabolic conditions, congenital disorders of autophagy.Management is currently largely supportive and symptomatic but better understanding of the underlying autophagy defect will hopefully inform the development of targeted therapies in future.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26927810 PMCID: PMC4772338 DOI: 10.1186/s13023-016-0399-x
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Clinical features of Vici syndrome
| Feature | Frequency | |
|---|---|---|
|
|
| ++++ |
| Profound developmental delay | ++++ | |
| Failure to thrive | ++++ | |
|
| ++++ | |
|
| ++++ | |
| Progressive microcephaly | +++ | |
|
| +++ | |
|
| +++ | |
|
| Presentation in neonatal period | +++ |
| Myopathy | +++ | |
| Seizures | ++ | |
| Absent reflexes (probable neuropathy) | ++ | |
| Thymic aplasia | + | |
| Sensorineural deafness | + | |
| Optic atrophy | + | |
| Renal tubular acidosis | + | |
| Cleft lip/palate | + | |
| Coarse facial features | + | |
| Hepatomegaly | + |
The 5 features initially considered to be diagnostic are indicated in italics. ++++ = present in almost all children, +++ = present in most children, ++ = present in more than half of children, + = present in some children
Fig. 1Clinical features of Vici syndrome. Note hypopigmentation in relation to ethnic (a–d, of Turkish origin) and familial (e–f) background. Coarsening of facial features with full lips and macroglossia resembling (lysosomal) storage disorders is noted in some older children (g). There is evidence of retinal hypopigmentation and optic atrophy on fundoscopy (h). From Cullup et al. Nature Genetics 2013; 45 (1):83–87, reproduced with permission
Fig. 2Schematic representation of the autophagy pathway. The autophagy pathway involves several tightly regulated steps, evolving from the initial formation of phagophores to autophagosomes, whose fusion with lysosomes results in the final structures of degradation, autolysosomes. The EPG5 protein plays a role in fusion events between autophagosomes, lysosomes, and, possibly, endosomes
Recommended investigations for the diagnosis and surveillance of patients with Vici syndrome
| Investigation | Presentation/Diagnosis [ | Surveillance |
|---|---|---|
|
| Baseline investigation [ | Not required |
|
| Baseline investigation [ | Not routinely required |
|
| Baseline investigation [ | Required surveillance for cataracts |
|
| Baseline investigation [ | Required surveillance for progressive cardiomyopathy |
|
| Baseline investigation [ | If clinically indicated |
|
| Baseline investigationc | Required surveillance for progressive immunedeficiency |
|
| Baseline investigation | If clinically indicated |
|
| Baseline investigation | If clinically indicated |
|
| Baseline investigation | If clinically indicated |
|
| Baseline investigation | If clinically indicated |
|
| Often clinically indicated [ | If clinically indicated |
|
| If clinically indicated | If clinically indicated |
|
| If clinically indicated | If clinically indicated |
|
| No longer indicated if genetic diagnosis has been establisheda | No longer indicated if genetic diagnosis has been established |
For more detail of recommended investigations and/or expected findings see a[14] b[16] c[6]
Syndromes showing phenotypical overlap with Vici syndrome (selection)
| Condition | Gene | Clinical feature | ||||||
|---|---|---|---|---|---|---|---|---|
| CNS | Cataract | Cardiomyopathy | Myopathy | Neuropathy | Immunodeficiency | Hypopigmentation | ||
| Vici syndrome |
| + | + | + | + | + | + | + |
| MSS |
| + | + | − | + | +a | − | − |
| CCFDN |
| + | + | − | + | + | − | − |
| Nathalie syndrome | ? | + | + | + | + | − | − | − |
| Griscelli syndrome 1 |
| + | − | − | ? | − | − | + |
| Griscelli syndrome 2 |
| + | − | − | ? | − | + | + |
| Griscelli syndrome 3 |
| − | − | − | ? | − | − | + |
| Elejalde syndrome |
| + | − | − | ? | − | − | + |
| CHS |
| + | − | − | + | (+) | + | + |
| HPS 2 |
| + | − | − | ? | + | − | + |
| Cohen syndrome |
| + | − | (+) | − | − | + | − |
| Danon disease |
| + | − | + | + | + | − | − |
| MEDNIK |
| + | (+) | − | − | + | − | − |
| CEDNIK |
| + | + | − | − | + | − | − |
MSS marinesco-sjoegren syndrome, CCFDN congenital cataracts, facial dysmorphism and neuropathy syndrome, CHS chediak-higashi syndrome, HPS2 hermanksy-pudlak syndrome type 2, MEDNIK mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis and keratoderma syndrome. + = feature present; - = feature absent; ? = not specifically investigated; (+) = feature controversial or not sufficiently documented; a = neuronopathy